BioPharma Credit PLC Performance

BOPCFDelisted Stock  USD 0.92  0.00  0.00%   
BioPharma Credit holds a performance score of 45 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.0926, which signifies not very significant fluctuations relative to the market. As returns on the market increase, BioPharma Credit's returns are expected to increase less than the market. However, during the bear market, the loss of holding BioPharma Credit is expected to be smaller as well. Use BioPharma Credit total risk alpha, as well as the relationship between the skewness and day median price , to analyze future returns on BioPharma Credit.

Risk-Adjusted Performance

Prime

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in BioPharma Credit PLC are ranked lower than 45 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile fundamental indicators, BioPharma Credit reported solid returns over the last few months and may actually be approaching a breakup point. ...more
  

BioPharma Credit Relative Risk vs. Return Landscape

If you would invest  89.00  in BioPharma Credit PLC on November 6, 2025 and sell it today you would earn a total of  3.00  from holding BioPharma Credit PLC or generate 3.37% return on investment over 90 days. BioPharma Credit PLC is currently producing 1.1236% returns and takes up 1.9461% volatility of returns over 90 trading days. Put another way, 17% of traded pink sheets are less volatile than BioPharma, and 78% of all traded equity instruments are likely to generate higher returns over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days horizon BioPharma Credit is expected to generate 2.59 times more return on investment than the market. However, the company is 2.59 times more volatile than its market benchmark. It trades about 0.58 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.11 per unit of risk.

BioPharma Credit Target Price Odds to finish over Current Price

The tendency of BioPharma Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.92 90 days 0.92 
about 17.05
Based on a normal probability distribution, the odds of BioPharma Credit to move above the current price in 90 days from now is about 17.05 (This BioPharma Credit PLC probability density function shows the probability of BioPharma Pink Sheet to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon BioPharma Credit has a beta of 0.0926 suggesting as returns on the market go up, BioPharma Credit average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding BioPharma Credit PLC will be expected to be much smaller as well. Additionally BioPharma Credit PLC has an alpha of 0.1901, implying that it can generate a 0.19 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   BioPharma Credit Price Density   
       Price  

Predictive Modules for BioPharma Credit

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BioPharma Credit PLC. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of BioPharma Credit's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.050.922.87
Details
Intrinsic
Valuation
LowRealHigh
0.040.782.73
Details
Naive
Forecast
LowNextHigh
0.020.902.85
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.890.920.95
Details

BioPharma Credit Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. BioPharma Credit is not an exception. The market had few large corrections towards the BioPharma Credit's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold BioPharma Credit PLC, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of BioPharma Credit within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.19
β
Beta against Dow Jones0.09
σ
Overall volatility
0.03
Ir
Information ratio 0.10

BioPharma Credit Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BioPharma Credit for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BioPharma Credit PLC can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
BioPharma Credit PLC is not yet fully synchronised with the market data
BioPharma Credit PLC has some characteristics of a very speculative penny stock
BioPharma Credit PLC has a very high chance of going through financial distress in the upcoming years
BioPharma is showing solid risk-adjusted performance over 90 days

BioPharma Credit Fundamentals Growth

BioPharma Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of BioPharma Credit, and BioPharma Credit fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioPharma Pink Sheet performance.

About BioPharma Credit Performance

By analyzing BioPharma Credit's fundamental ratios, stakeholders can gain valuable insights into BioPharma Credit's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioPharma Credit has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioPharma Credit has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. The company was incorporated in 2016 and is based in Exeter, the United Kingdom. Biopharma Credit is traded on OTC Exchange in the United States.

Things to note about BioPharma Credit PLC performance evaluation

Checking the ongoing alerts about BioPharma Credit for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for BioPharma Credit PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
BioPharma Credit PLC is not yet fully synchronised with the market data
BioPharma Credit PLC has some characteristics of a very speculative penny stock
BioPharma Credit PLC has a very high chance of going through financial distress in the upcoming years
BioPharma is showing solid risk-adjusted performance over 90 days
Evaluating BioPharma Credit's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate BioPharma Credit's pink sheet performance include:
  • Analyzing BioPharma Credit's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioPharma Credit's stock is overvalued or undervalued compared to its peers.
  • Examining BioPharma Credit's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating BioPharma Credit's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioPharma Credit's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of BioPharma Credit's pink sheet. These opinions can provide insight into BioPharma Credit's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating BioPharma Credit's pink sheet performance is not an exact science, and many factors can impact BioPharma Credit's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Other Consideration for investing in BioPharma Pink Sheet

If you are still planning to invest in BioPharma Credit PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BioPharma Credit's history and understand the potential risks before investing.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
AI Portfolio Prophet
Use AI to generate optimal portfolios and find profitable investment opportunities